References
- Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-58. https://doi.org/10.1016/j.clinthera.2007.08.008
- Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12: 1042-9. https://doi.org/10.1007/s001980170015
- Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 2010; 68: 797-804. https://doi.org/10.1016/j.joms.2009.10.026
- Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TriaI. JAMA 1998; 280: 2077-82. https://doi.org/10.1001/jama.280.24.2077
- Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41. https://doi.org/10.1016/S0140-6736(96)07088-2
- Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-8.
- Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52. https://doi.org/10.1001/jama.282.14.1344
- Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-46. https://doi.org/10.1002/art.21918
- Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s-30s. https://doi.org/10.1158/1078-0432.CCR-06-0843
- Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003; 42: 863-81. https://doi.org/10.2165/00003088-200342100-00001
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35: 119-30. https://doi.org/10.1111/j.1747-4477.2009.00213.x
- Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-91. https://doi.org/10.1359/jbmr.0707onj
- O'Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 2012; 70: 1844-53. https://doi.org/10.1016/j.joms.2011.08.033
- Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 2010; 68: 2241-7. https://doi.org/10.1016/j.joms.2010.05.043
- Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-23. https://doi.org/10.1016/j.joms.2006.10.061
- Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68: 790-6. https://doi.org/10.1016/j.joms.2009.09.017
- Taylor T, Bryant C, Popat S. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital. Br Dent J 2013; 214: E18. https://doi.org/10.1038/sj.bdj.2013.327
- Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009; 140: 61-6. https://doi.org/10.14219/jada.archive.2009.0019
- Hansen PJ, Knitschke M, Draenert FG, Irle S, Neff A. Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk? Clin Oral Investig 2013; 17: 1829-37. https://doi.org/10.1007/s00784-012-0873-3
- Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-410. https://doi.org/10.1016/j.joms.2007.08.003
Cited by
- Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study vol.29, pp.10, 2017, https://doi.org/10.1007/s00198-018-4621-7
- Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis vol.224, pp.1, 2018, https://doi.org/10.1038/sj.bdj.2017.1001
- Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw vol.79, pp.2, 2017, https://doi.org/10.1007/s00393-019-0606-y
- Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study vol.10, pp.13, 2020, https://doi.org/10.3390/app10134487